Robot-assisted surgery has evolved into a crucial treatment for prostate cancer(PCa).However,from its appearance to today,brain-computer interface,virtual reality,and metaverse have revolutionized the field of robot-a...Robot-assisted surgery has evolved into a crucial treatment for prostate cancer(PCa).However,from its appearance to today,brain-computer interface,virtual reality,and metaverse have revolutionized the field of robot-assisted surgery for PCa,presenting both opportunities and challenges.Especially in the context of contemporary big data and precision medicine,facing the heterogeneity of PCa and the complexity of clinical problems,it still needs to be continuously upgraded and improved.Keeping this in mind,this article summarized the 5 stages of the historical development of robot-assisted surgery for PCa,encompassing the stages of emergence,promotion,development,maturity,and intelligence.Initially,safety concerns were paramount,but subsequent research and engineering advancements have focused on enhancing device efficacy,surgical technology,and achieving precise multi modal treatment.The dominance of da Vinci robot-assisted surgical system has seen this evolution intimately tied to its successive versions.In the future,robot-assisted surgery for PCa will move towards intelligence,promising improved patient outcomes and personalized therapy,alongside formidable challenges.To guide future development,we propose 10 significant prospects spanning clinical,research,engineering,materials,social,and economic domains,envisioning a future era of artificial intelligence in the surgical treatment of PCa.展开更多
Objective: Human embryonic stem cells (hESCs) have recently been reported as an unlimited source of mesenchymal stem cells (MSCs).The present study not only provides an identical and clinically compliant MSC source de...Objective: Human embryonic stem cells (hESCs) have recently been reported as an unlimited source of mesenchymal stem cells (MSCs).The present study not only provides an identical and clinically compliant MSC source derived from hESCs (hESC-MSCs),but also describes the immunomodulative effects of hESC-MSCs in vitro and in vivo for a carbon tetrachloride (CCl4)-induced liver inflammation model.Methods: Undifferentiated hESCs were treated with Rho-associated kinase (ROCK) inhibitor and induced to fibroblast-looking cells.These cells were tested for their surface markers and multilineage differentiation capability.Further more,we analyzed their immune characteristics by mixed lymphocyte reactions (MLRs) and animal experiments.Results: hESC-MSCs show a homogenous fibroblastic morphology that resembles bone marrow-derived MSCs (BM-MSCs).The cell markers and differentiation potential of hESC-MSCs are also similar to those of BM-MSCs.Unlike their original cells,hESC-MSCs possess poor immunogenicity and can survive and be engrafted into a xenogenic immunocompetent environment.Conclusions: The hESC-MSCs demonstrate strong inhibitory effects on lymphocyte proliferation in vitro and anti-inflammatory infiltration properties in vivo.This study offers information essential to the applications of hESC-MSC-based therapies and evidence for the therapeutic mechanisms of action.展开更多
To the Editor:Pancreatic cancer (PC) is one of the most deadly cancers due to the difficulty of its early diagnosis.Most patients have developed an unresectable PC when diagnosed [1].According to GLOBOCAN2018 estimate...To the Editor:Pancreatic cancer (PC) is one of the most deadly cancers due to the difficulty of its early diagnosis.Most patients have developed an unresectable PC when diagnosed [1].According to GLOBOCAN2018 estimates,PC ranked the 11th most common cancer in the world counting 458 918 new cases and causing 432 242 deaths(4.5%of all deaths caused by cancer) in 2018 [2].展开更多
Objective： To study whether Tongxinluo （TXL） can induce angiogenesis in bone marrow mesenchymal stem cells （MSCs）, and to investigate the underlying mechanism. Methods： Bone marrow MSCs were obtained from male S...Objective： To study whether Tongxinluo （TXL） can induce angiogenesis in bone marrow mesenchymal stem cells （MSCs）, and to investigate the underlying mechanism. Methods： Bone marrow MSCs were obtained from male Sprague-Dawley rats. We established an angiogenesis model in vitro via matrigel experiment. MSCs were seeded on matrigel coated 24-well plates, and treated by TXL 50 and 100 mg/L. After 24 h, we observed the tube formations of MSCs in the matrigel. Cell migration ability was examined by wound scratch test and transwell assay. Expressions of vascular endothelial growth factor （VEGF）, fetal liver kinase-1 （FIk-1）, matrix metalloproteinase-2 （MMP-2）, MMP-9, and tissue inhibitor of metalloproteinase-2 （TIMP-2） were analyzed at the protein level by Western blot. Gelatin zymography assay was applied to investigating the MSC paracrine abilities of pro-MMP-2 and activated MMP-2. Results： TXL promoted MSC tube formation in matrigel. The ratio of TXL 100 mg/L treated-MSC tubular length was increased 3.04-fold compared to the control group （P〈0.05）. Scratch test and transwell assay showed that TXL could improve the cell migration ability of MSCs. Western blot experiments showed that TXL promoted MSC synthesis of MMP-2, but it had no influence on the expressions of MMP-9 and TIMP-2. This effect was confirmed by gelatin zymography assay, which showed that TXL increased MSC secretion of pro-MMP-2 and activated MMP-2. VEGF expression of TXL treated-MSCs was increased compared to the control group. The expression of FIk-1 was not different among the groups. Conclusions： This study demonstrates that TXL can promote the tube formation of MSCs, and the underlying mechanisms are associated with increased migration ability of MSCs and the up-regulation of MMP-2 and VEGF expressions.展开更多
OBJECTIVE To study the pharmacokinetics change of schisandra chinensis under the pathological condition of liver dysfunction for safe and rational use of herbal medicines.METHODS The metabolism of four effective ligna...OBJECTIVE To study the pharmacokinetics change of schisandra chinensis under the pathological condition of liver dysfunction for safe and rational use of herbal medicines.METHODS The metabolism of four effective lignans from schisandra chinensis(SC),schisandrin,schisantherin A,deoxyshisandrin and γ-schisandrin was studied using microsomes from patients with advanced hepato.cellular carcinoma.In situ intestinal and hepatic perfusions were conducted to clarify the contributions from impairments of gut and liver on the pharmacokinetics of the four schisandra lignans in CCl4-intoxi.cated rats.The metabolism in rat and human liver microsomes and transport in Caco-2 monolayer cell model were studied to reveal the key factors for the in vivo disposition of the four lignans.RESULTS When SC alcoholic extract was orally administrated to CCl4-intoxicated rat for a short term(4 d),the pharmacokinetics of four active SC lignans was significantly changed while its hepatoprotective effect was not obviously observed.The plasma concentrations of the four schisandra lignans were dramatical.ly elevated compared with the control.The Cmax,AUC and MRT were all increased or prolonged signif.icantly while parameter CLz/F was obviously reduced in rat pretreated with CCl4.In hepatic perfusion study and liver microsomes incubation,it was found that the hepatic metabolism of the four lignans was markedly decreased mainly due to the activity reduction of multiple CYP450 isoenzymes involved the metabolism,which,eventually,might lead to the alternation of their pharmacokinetic profiles in CCl4-intoxicated rats or patients with advanced hepatocellular carcinoma.CONCLUSION The pharmacoki.netic studies of SC components in pathological situation of liver dysfunction are expected to provide useful data for rational and safe application of SC preparations in clinic or further pharmacological and toxicological research.展开更多
BACKGROUND Pulmonary artery(PA)aneurysms are usually diagnosed radiographically and present as small or large lesions resembling inflammation or a neoplasm on chest radiography.It has rarely been reported as an endobr...BACKGROUND Pulmonary artery(PA)aneurysms are usually diagnosed radiographically and present as small or large lesions resembling inflammation or a neoplasm on chest radiography.It has rarely been reported as an endobronchial mass.CASE SUMMARY We report the case of a 64-year-old man who presented with recurrent hemoptysis.Bronchoscopy revealed a tumorous protrusion blocking the right middle lobe bronchus,which was confirmed to be a PA aneurysm using endobronchial ultrasound bronchoscopy and computed tomography angiography.CONCLUSION Although endobronchial PA aneurysms are rare,bronchoscopists need to add this lesion to the list of endobronchial masses for which a biopsy is to be assiduously avoided.展开更多
基金supported by the Fundamental Research Funds for the Central Universities(2023SCU12057)the National Natural Science Foundation of China(82373106,82372831,and 32270690).
文摘Robot-assisted surgery has evolved into a crucial treatment for prostate cancer(PCa).However,from its appearance to today,brain-computer interface,virtual reality,and metaverse have revolutionized the field of robot-assisted surgery for PCa,presenting both opportunities and challenges.Especially in the context of contemporary big data and precision medicine,facing the heterogeneity of PCa and the complexity of clinical problems,it still needs to be continuously upgraded and improved.Keeping this in mind,this article summarized the 5 stages of the historical development of robot-assisted surgery for PCa,encompassing the stages of emergence,promotion,development,maturity,and intelligence.Initially,safety concerns were paramount,but subsequent research and engineering advancements have focused on enhancing device efficacy,surgical technology,and achieving precise multi modal treatment.The dominance of da Vinci robot-assisted surgical system has seen this evolution intimately tied to its successive versions.In the future,robot-assisted surgery for PCa will move towards intelligence,promising improved patient outcomes and personalized therapy,alongside formidable challenges.To guide future development,we propose 10 significant prospects spanning clinical,research,engineering,materials,social,and economic domains,envisioning a future era of artificial intelligence in the surgical treatment of PCa.
基金Project (No.2007CB947804) supported by the National Basic Research Program (973) of China
文摘Objective: Human embryonic stem cells (hESCs) have recently been reported as an unlimited source of mesenchymal stem cells (MSCs).The present study not only provides an identical and clinically compliant MSC source derived from hESCs (hESC-MSCs),but also describes the immunomodulative effects of hESC-MSCs in vitro and in vivo for a carbon tetrachloride (CCl4)-induced liver inflammation model.Methods: Undifferentiated hESCs were treated with Rho-associated kinase (ROCK) inhibitor and induced to fibroblast-looking cells.These cells were tested for their surface markers and multilineage differentiation capability.Further more,we analyzed their immune characteristics by mixed lymphocyte reactions (MLRs) and animal experiments.Results: hESC-MSCs show a homogenous fibroblastic morphology that resembles bone marrow-derived MSCs (BM-MSCs).The cell markers and differentiation potential of hESC-MSCs are also similar to those of BM-MSCs.Unlike their original cells,hESC-MSCs possess poor immunogenicity and can survive and be engrafted into a xenogenic immunocompetent environment.Conclusions: The hESC-MSCs demonstrate strong inhibitory effects on lymphocyte proliferation in vitro and anti-inflammatory infiltration properties in vivo.This study offers information essential to the applications of hESC-MSC-based therapies and evidence for the therapeutic mechanisms of action.
文摘To the Editor:Pancreatic cancer (PC) is one of the most deadly cancers due to the difficulty of its early diagnosis.Most patients have developed an unresectable PC when diagnosed [1].According to GLOBOCAN2018 estimates,PC ranked the 11th most common cancer in the world counting 458 918 new cases and causing 432 242 deaths(4.5%of all deaths caused by cancer) in 2018 [2].
基金Project supported by the Natural Science Foundation of Zhejiang Province (No. Y2090308)the Traditional Chinese Medicine Project of Zhejiang Province (No. 391030-W50806)the Key Lab of Traditional Chinese Medicine of Zhejiang Province,China (No. ZK23812)
文摘Objective： To study whether Tongxinluo （TXL） can induce angiogenesis in bone marrow mesenchymal stem cells （MSCs）, and to investigate the underlying mechanism. Methods： Bone marrow MSCs were obtained from male Sprague-Dawley rats. We established an angiogenesis model in vitro via matrigel experiment. MSCs were seeded on matrigel coated 24-well plates, and treated by TXL 50 and 100 mg/L. After 24 h, we observed the tube formations of MSCs in the matrigel. Cell migration ability was examined by wound scratch test and transwell assay. Expressions of vascular endothelial growth factor （VEGF）, fetal liver kinase-1 （FIk-1）, matrix metalloproteinase-2 （MMP-2）, MMP-9, and tissue inhibitor of metalloproteinase-2 （TIMP-2） were analyzed at the protein level by Western blot. Gelatin zymography assay was applied to investigating the MSC paracrine abilities of pro-MMP-2 and activated MMP-2. Results： TXL promoted MSC tube formation in matrigel. The ratio of TXL 100 mg/L treated-MSC tubular length was increased 3.04-fold compared to the control group （P〈0.05）. Scratch test and transwell assay showed that TXL could improve the cell migration ability of MSCs. Western blot experiments showed that TXL promoted MSC synthesis of MMP-2, but it had no influence on the expressions of MMP-9 and TIMP-2. This effect was confirmed by gelatin zymography assay, which showed that TXL increased MSC secretion of pro-MMP-2 and activated MMP-2. VEGF expression of TXL treated-MSCs was increased compared to the control group. The expression of FIk-1 was not different among the groups. Conclusions： This study demonstrates that TXL can promote the tube formation of MSCs, and the underlying mechanisms are associated with increased migration ability of MSCs and the up-regulation of MMP-2 and VEGF expressions.
基金supported by National Science and Technology Major Project(2016ZX09J161042012ZX09301003-002-001)
文摘OBJECTIVE To study the pharmacokinetics change of schisandra chinensis under the pathological condition of liver dysfunction for safe and rational use of herbal medicines.METHODS The metabolism of four effective lignans from schisandra chinensis(SC),schisandrin,schisantherin A,deoxyshisandrin and γ-schisandrin was studied using microsomes from patients with advanced hepato.cellular carcinoma.In situ intestinal and hepatic perfusions were conducted to clarify the contributions from impairments of gut and liver on the pharmacokinetics of the four schisandra lignans in CCl4-intoxi.cated rats.The metabolism in rat and human liver microsomes and transport in Caco-2 monolayer cell model were studied to reveal the key factors for the in vivo disposition of the four lignans.RESULTS When SC alcoholic extract was orally administrated to CCl4-intoxicated rat for a short term(4 d),the pharmacokinetics of four active SC lignans was significantly changed while its hepatoprotective effect was not obviously observed.The plasma concentrations of the four schisandra lignans were dramatical.ly elevated compared with the control.The Cmax,AUC and MRT were all increased or prolonged signif.icantly while parameter CLz/F was obviously reduced in rat pretreated with CCl4.In hepatic perfusion study and liver microsomes incubation,it was found that the hepatic metabolism of the four lignans was markedly decreased mainly due to the activity reduction of multiple CYP450 isoenzymes involved the metabolism,which,eventually,might lead to the alternation of their pharmacokinetic profiles in CCl4-intoxicated rats or patients with advanced hepatocellular carcinoma.CONCLUSION The pharmacoki.netic studies of SC components in pathological situation of liver dysfunction are expected to provide useful data for rational and safe application of SC preparations in clinic or further pharmacological and toxicological research.
基金Supported by Doctoral Research Foundation of The First Affiliated Hospital of Kunming Medical University,No.2022BS030and Scientific Research Foundation of Yunnan Education Department,No.2023Y0630.
文摘BACKGROUND Pulmonary artery(PA)aneurysms are usually diagnosed radiographically and present as small or large lesions resembling inflammation or a neoplasm on chest radiography.It has rarely been reported as an endobronchial mass.CASE SUMMARY We report the case of a 64-year-old man who presented with recurrent hemoptysis.Bronchoscopy revealed a tumorous protrusion blocking the right middle lobe bronchus,which was confirmed to be a PA aneurysm using endobronchial ultrasound bronchoscopy and computed tomography angiography.CONCLUSION Although endobronchial PA aneurysms are rare,bronchoscopists need to add this lesion to the list of endobronchial masses for which a biopsy is to be assiduously avoided.
